TEM on Nasdaq
Tempus AI
Logo: Tempus AI, Public domain, via Wikimedia Commons5
American health technology company
Tempus AI, Inc. (formerly Tempus Labs) is an American health technology company founded in 2015 by Eric Lefkofsky in Chicago, Illinois. It was established by Lefkofsky soon after his wife was diagnosed with breast cancer. Tempus uses data and artificial intelligence (AI) to create precision medicine services, including diagnostics, for oncology, cardiology, radiology, and depression.3 Wikipedia text CC BY-SA 4.0
Price unavailable
Last updated Oct 21, 2026.
Overview
Compare with Outbrain, Kanzhun Ltd or Bumble, or pick any stock.
- TickerTEM on Nasdaq1
- IndustryServices-Computer Programming, Data Processing, Etc.1
- HeadquartersChicago1
- Websitewww.tempus.com
- Incorporated inNV7
- Business address600 West Chicago Avenue, Suite 510, Chicago, Il 606547
- Filer categoryLarge accelerated filer7
- Legal formCorporation4
- LEI2549009LA0KWRAGQBX504
- StatusActive4
- LEI statusIssued and current4
- Registered addressC/O THE CORPORATION TRUST COMPANY, 19801 Wilmington, United States4
- Registered withDivision of Corporations, Department of State, 58107584
See how the biggest companies compare on our leaderboards
Tempus AI, Inc. (formerly Tempus Labs) is an American health technology company founded in 2015 by Eric Lefkofsky in Chicago, Illinois. It was established by Lefkofsky soon after his wife was diagnosed with breast cancer. Tempus uses data and artificial intelligence (AI) to create precision medicine services, including diagnostics, for oncology, cardiology, radiology, and depression. The company went public on the Nasdaq on June 14, 2024, under the ticker symbol "TEM."3
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
-19.9%Operating margin6
-19.3%Net margin6
83.4%Revenue growth, 20256
-49.9%Return on equity6
-$239.1MFree cash flow6
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Products and services
Diagnostics brought in 75% of the revenue Tempus AI broke down this way in fiscal 2025.
Products and services by year
| Products and services | 2023 | 2024 | 2025 |
|---|---|---|---|
| Diagnostics | $363.0M | $451.7M | $955.4M |
| Insights Product | $117.6M | $186.8M | $257.7M |
| Trials Product | $45.6M | $42.4M | $38.5M |
| AI Applications | $5.1M | $12.3M | $20.1M |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Research and development14¢$172.9M
- Selling, general and admin58¢$731.7M
- Other costs25¢$315.4M
- Income tax4¢$51.7M
Out of $1.3B in revenue.6 The company lost money this year.
Financial statements
Every line of the income statement as filed: the last 4 fiscal years, latest first.6
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Total net revenue | $1.3B | $693.4M | $531.8M | |
| Technology research and development | $146.1M | $167.5M | $95.2M | |
| Research and development | $172.9M | $149.3M | $90.3M | |
| Selling, general and administrative | $731.7M | $755.4M | $296.8M | |
| Total cost and operating expenses | $1.5B | $1.4B | $727.9M | |
| Loss from operations | -$252.9M | -$691.1M | -$196.1M | |
| Interest income | $12.6M | $11.1M | $7.6M | |
| Interest expense | -$70.3M | -$53.7M | -$46.9M | |
| Loss on debt extinguishment | -$12.0M | $0 | $0 | |
| Other income, net | $31.4M | $32.3M | $21.8M | |
| Loss before benefit from (provision for) income taxes | -$291.1M | -$701.3M | -$213.5M | |
| benefit from (Provision for) income taxes | $51.7M | -$266.0K | -$288.0K | |
| losses from equity method investments | -$5.6M | -$4.2M | -$301.0K | |
| Net Loss | -$245.0M | -$705.8M | -$214.1M | |
| Accretion of convertible preferred stock to redemption value | $0 | $0 | -$4.3M | |
| Dividends on Series A, B, B-1, B-2, C, D, E, F, G, G-3, and G-4 preferred shares | $0 | -$39.3M | -$44.5M | |
| Cumulative undeclared dividends on Series C preferred shares | $0 | -$1.2M | -$3.0M | |
| Net loss attributable to common shareholders, basic | -$245.0M | -$746.3M | -$266.0M | |
| Net loss attributable to common shareholders, diluted | -$245.0M | -$746.3M | -$266.0M | |
| Net loss per share attributable to common shareholders, basic | -$1.41 | -$6.23 | -$4.20 | |
| Net loss per share attributable to common shareholders, diluted | -$1.41 | -$6.23 | -$4.20 | |
| Weighted-average shares outstanding used to compute net loss per share, basic | 174.3K shares | 119.8K shares | 63.3K shares | 63.3K shares |
| Weighted-average shares outstanding used to compute net loss per share, diluted | 174.3K shares | 119.8K shares | 63.3K shares | |
| Foreign currency translation adjustment | $808.0K | $89.0K | -$13.0K | |
| Comprehensive loss | -$244.2M | -$705.7M | -$214.1M |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.6
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $604.8M | $341.0M | $165.8M | |
| Accounts receivable, net of allowances of $2,755 and $1,141 at December 31, 2025 and 2024, respectively | $311.2M | $154.8M | ||
| Inventory | $51.7M | $38.4M | ||
| Related party asset | $8.8M | |||
| Prepaid expenses and other current assets | $40.5M | $26.1M | ||
| Marketable equity securities | $150.2M | $107.3M | ||
| Total current assets | $1.2B | $667.6M | ||
| Property and equipment, net | $89.2M | $58.1M | ||
| Goodwill | $470.2M | $73.3M | $73.4M | |
| Intangible assets, net | $355.3M | $11.7M | ||
| Investments and other assets | $21.1M | $8.3M | ||
| Investment in joint venture | $86.6M | $91.5M | ||
| Related party asset, less current portion | $16.2M | |||
| Operating lease right-of-use assets | $64.5M | $14.8M | ||
| Restricted cash | $4.7M | $881.0K | ||
| Total Assets | $2.3B | $926.1M | ||
| Accounts payable | $82.0M | $53.8M | ||
| Accrued expenses | $155.4M | $130.4M | ||
| Deferred other income | $16.0M | $16.0M | ||
| Other current liabilities | $8.7M | $7.0M | ||
| Operating lease liabilities | $13.4M | $6.5M | ||
| Accrued data licensing fees | $4.4M | $1.5M | ||
| Total current liabilities | $372.4M | $291.1M | ||
| Operating lease liabilities, less current portion | $74.3M | $26.2M | ||
| Convertible promissory note | $208.7M | $168.2M | ||
| Other long-term liabilities | $56.6M | $16.0M | ||
| Revolving credit facility | $100.0M | |||
| Interest payable | $12.4M | $70.5M | ||
| Long-term debt, net | $202.8M | $267.2M | ||
| Convertible senior notes, net | $728.1M | |||
| Deferred other income, less current portion | $8.0M | $23.9M | ||
| Deferred revenue, less current portion | $20.4M | $6.7M | ||
| Total Liabilities | $1.8B | $869.8M | ||
| Convertible redeemable preferred stock, $0.0001 par value, 20,000,000 shares authorized at December 31, 2025 and 2024, respectively, no shares issued and outstanding at December 31, 2025 and 2024 | $0 | $0 | ||
| Treasury Stock, 183,229 and 145,466 shares at December 31, 2025 and 2024, respectively, at cost | -$6.6M | -$3.6M | ||
| Additional Paid-In Capital | $2.9B | $2.2B | ||
| Accumulated Other Comprehensive Income | $902.0K | $94.0K | ||
| Accumulated deficit | -$2.4B | -$2.2B | ||
| Total Stockholders' equity | $491.3M | $56.3M | -$1.4B | -$1.1B |
| Total Liabilities, Convertible redeemable preferred stock, and Stockholders' equity | $2.3B | $926.1M | ||
| Accounts receivable, net of allowances | $2.8M | $1.1M | ||
| Related party deferred revenue | $92.7M | $76.0M | ||
| Treasury stock common shares | 183.2K shares | 145.5K shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $604.8M | $341.0M | $165.8M | |
| Accounts receivable, net of allowances of $2,755 and $1,141 at December 31, 2025 and 2024, respectively | $311.2M | $154.8M | ||
| Inventory | $51.7M | $38.4M | ||
| Related party asset | $8.8M | |||
| Prepaid expenses and other current assets | $40.5M | $26.1M | ||
| Marketable equity securities | $150.2M | $107.3M | ||
| Total current assets | $1.2B | $667.6M | ||
| Property and equipment, net | $89.2M | $58.1M | ||
| Goodwill | $470.2M | $73.3M | $73.4M | |
| Intangible assets, net | $355.3M | $11.7M | ||
| Investments and other assets | $21.1M | $8.3M | ||
| Investment in joint venture | $86.6M | $91.5M | ||
| Related party asset, less current portion | $16.2M | |||
| Operating lease right-of-use assets | $64.5M | $14.8M | ||
| Restricted cash | $4.7M | $881.0K | ||
| Total Assets | $2.3B | $926.1M | ||
| Accounts payable | $82.0M | $53.8M | ||
| Accrued expenses | $155.4M | $130.4M | ||
| Deferred other income | $16.0M | $16.0M | ||
| Other current liabilities | $8.7M | $7.0M | ||
| Operating lease liabilities | $13.4M | $6.5M | ||
| Accrued data licensing fees | $4.4M | $1.5M | ||
| Total current liabilities | $372.4M | $291.1M | ||
| Operating lease liabilities, less current portion | $74.3M | $26.2M | ||
| Convertible promissory note | $208.7M | $168.2M | ||
| Other long-term liabilities | $56.6M | $16.0M | ||
| Revolving credit facility | $100.0M | |||
| Interest payable | $12.4M | $70.5M | ||
| Long-term debt, net | $202.8M | $267.2M | ||
| Convertible senior notes, net | $728.1M | |||
| Deferred other income, less current portion | $8.0M | $23.9M | ||
| Deferred revenue, less current portion | $20.4M | $6.7M | ||
| Total Liabilities | $1.8B | $869.8M | ||
| Convertible redeemable preferred stock, $0.0001 par value, 20,000,000 shares authorized at December 31, 2025 and 2024, respectively, no shares issued and outstanding at December 31, 2025 and 2024 | $0 | $0 | ||
| Treasury Stock, 183,229 and 145,466 shares at December 31, 2025 and 2024, respectively, at cost | -$6.6M | -$3.6M | ||
| Additional Paid-In Capital | $2.9B | $2.2B | ||
| Accumulated Other Comprehensive Income | $902.0K | $94.0K | ||
| Accumulated deficit | -$2.4B | -$2.2B | ||
| Total Stockholders' equity | $491.3M | $56.3M | -$1.4B | -$1.1B |
| Total Liabilities, Convertible redeemable preferred stock, and Stockholders' equity | $2.3B | $926.1M | ||
| Accounts receivable, net of allowances | $2.8M | $1.1M | ||
| Related party deferred revenue | $92.7M | $76.0M | ||
| Treasury stock common shares | 183.2K shares | 145.5K shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 3 fiscal years, latest first.6
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net (loss) income | -$245.0M | -$705.8M | -$214.1M |
| Change in fair value of warrant liability | $0 | $42.4M | -$8.0M |
| Gain on warrant termination | $0 | -$39.1M | $0 |
| Reversal of warrant contract asset amortization | $0 | -$16.3M | $0 |
| Stock-based compensation | $124.7M | $534.1M | $0 |
| Gain on warrant exercise | $0 | -$173.0K | $0 |
| Gain on marketable equity securities | -$16.5M | -$12.1M | -$9.8M |
| Loss on disposal of property and equipment | $415.0K | $0 | $0 |
| Loss on debt extinguishment | $12.0M | $0 | $0 |
| Deferred income taxes | -$52.7M | $0 | $0 |
| Losses from equity method investments | $5.6M | $4.2M | $301.0K |
| Amortization of original issue discount | $4.1M | $1.4M | $1.1M |
| Amortization of deferred financing fees | $484.0K | $510.0K | $510.0K |
| Change in fair value of contingent consideration | $0 | $72.0K | -$400.0K |
| Change in fair value of holdback liability | -$1.3M | $0 | $0 |
| Amortization of warrant contract asset | $0 | $4.8M | $5.2M |
| Depreciation and amortization | $102.3M | $37.2M | $33.0M |
| Provision for bad debt expense | $2.6M | $680.0K | $1.6M |
| Provision for obsolete inventory | $1.3M | $0 | $0 |
| Amortization of finance right-of-use lease assets | $0 | $0 | $283.0K |
| Change in fair value of warrant asset | $0 | -$18.3M | -$4.1M |
| Non-cash operating lease costs | $11.6M | $6.0M | $6.8M |
| Minimum accretion expense | $268.0K | $197.0K | $90.0K |
| Impairment of intangible assets | $0 | $0 | $7.4M |
| PIK interest added to principal | $10.5M | $8.8M | $3.6M |
| Inventory | -$3.4M | -$9.5M | -$6.6M |
| Prepaid expenses and other current assets | -$1.7M | -$13.7M | -$6.5M |
| Investments and other assets | -$17.3M | -$751.0K | -$4.2M |
| Accounts payable | -$7.2M | -$23.9M | -$23.4M |
| Related party asset | -$25.0M | $0 | $0 |
| Deferred revenue | -$7.0M | -$20.9M | -$26.4M |
| Deferred other income | -$16.0M | $39.9M | $0 |
| Accrued data licensing fees | $3.0M | -$5.0M | -$9.1M |
| Accrued expenses & other | -$12.8M | $50.5M | $38.6M |
| Interest payable | $14.2M | $15.1M | $15.8M |
| Operating lease liabilities | -$14.9M | -$8.6M | -$8.8M |
| Net cash used in operating activities | -$218.1M | -$189.0M | -$214.3M |
| Purchases of property and equipment | -$21.0M | -$22.1M | -$34.6M |
| Proceeds from sale of marketable equity securities | $8.3M | $23.1M | $0 |
| Purchases of marketable equity securities | -$2.7M | -$36.2M | $0 |
| Business combinations, net of cash acquired | -$376.7M | $0 | -$5.7M |
| Investment in joint venture | $0 | -$95.2M | $0 |
| Capitalized software costs | -$6.2M | $0 | $0 |
| Net cash used in investing activities | -$398.4M | -$130.4M | -$40.3M |
| Proceeds from issuance of common stock in connection with initial public offering, net of underwriting discounts and commissions | $0 | $382.0M | $0 |
| Tax withholding related to net share settlement of restricted stock units | $0 | -$69.9M | $0 |
| Issuance of Series G-4 Preferred Stock, net of offering costs | $0 | $0 | $44.9M |
| Issuance of Series G-5 Preferred Stock | $0 | $199.8M | $0 |
| Principal payments on finance lease liabilities | $0 | $0 | -$288.0K |
| Purchase of treasury stock | -$3.0M | $0 | -$3.6M |
| Payment of deferred offering costs | -$806.0K | -$8.8M | -$698.0K |
| Dividends paid | $0 | -$5.6M | -$5.6M |
| Proceeds from revolving credit facility, net of original issue discount | $98.0M | $0 | $0 |
| Proceeds from long-term debt, net of original issue discount | $196.0M | $0 | $82.9M |
| Proceeds from convertible senior notes, net of initial purchasers' discount | $726.5M | $0 | $0 |
| Payment of deferred financing fees | -$1.5M | $0 | $0 |
| Payment of indemnity holdback related to acquisition | $0 | -$813.0K | $0 |
| G-4 Special Payment | $0 | -$2.2M | $0 |
| Principal payments on long-term debt | -$276.9M | $0 | $0 |
| Prepayment premium on long-term debt | -$7.8M | $0 | $0 |
| Purchases of capped call | -$41.8M | $0 | $0 |
| Proceeds from issuance of common stock in connection with at-the-market offering, net of commissions | $195.5M | $0 | $0 |
| Net cash provided by financing activities | $884.1M | $494.3M | $117.5M |
| Effect of foreign exchange rates on cash | -$62.0K | $336.0K | -$19.0K |
| Net increase (decrease) in Cash, Cash Equivalents and Restricted Cash | $267.6M | $175.2M | -$137.1M |
| Cash paid during the year for interest | $44.0M | $28.0M | $16.9M |
| Cash paid for income taxes | $654.0K | $206.0K | $161.0K |
| Marketable equity securities received on accounts receivable | $32.0M | $22.0M | $22.0M |
| Dividends Payable | $0 | $5.5M | $12.5M |
| Purchases of property and equipment, accrued but not paid | $5.5M | $4.3M | $6.1M |
| Redemption of convertible promissory note | $32.0M | $24.9M | $28.0M |
| Non-voting common stock issued in connection with business combinations | $0 | $344.0K | $9.2M |
| Accretion of convertible preferred stock to redemption value | $0 | $0 | $4.3M |
| Deferred offering costs, accrued but not yet paid | $47.0K | $0 | $3.5M |
| Deferred financing fees, accrued but not yet paid | $226.0K | $0 | $0 |
| Reclassification of deferred offering costs to additional paid-in capital upon at-the-market offering | $821.0K | $0 | $0 |
| Operating lease liabilities arising from obtaining right-of-use assets | $22.7M | $2.0M | $1.1M |
| Conversion of redeemable convertible preferred stock to common stock in connection with initial public offering | $0 | $1.3B | $0 |
| Taxes related to net share settlement of restricted stock units not yet paid | $0 | $20.0K | $0 |
| Reclassification of deferred offering costs to additional paid-in capital upon initial public offering | $0 | $12.3M | $0 |
| Class A Common Stock issued in connection with business combinations | $403.2M | $0 | $0 |
| Class A Common Stock issued in connection with license agreement | $1.4M | $0 | $0 |
| Issuance of warrant | $0 | $0 | $4.2M |
| Issuance of common stock in connection with contingent consideration | $0 | $847.0K | $0 |
| Convertible promissory note principal reset due to amendment | $72.5M | $0 | $0 |
| Increase in related party accounts receivable | $90.4M | $61.0M | $7.3M |
No quarter-by-quarter statement was filed.
Corporate structure
Tempus AI sits at the top of its group. 8 entities, 7 countries on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of Tempus AI
- BAILLIE GIFFORD & CO Filed SCHEDULE 13G/A on Tempus AI, latest May 7, 2026 (4 filings since Nov 5, 2024)
- VANGUARD GROUP INC Filed SCHEDULE 13G/A on Tempus AI, latest Mar 27, 2026 (2 filings since Oct 31, 2025)
- ARK Investment Management LLC Filed SCHEDULE 13G on Tempus AI, latest Mar 6, 2026
- Eric P. Lefkofsky Filed SCHEDULE 13G/A on Tempus AI, latest Feb 10, 2026 (3 filings since Nov 12, 2024)
- Red Sky Ventures LLC Filed SCHEDULE 13G/A on Tempus AI, latest Nov 13, 2025 (4 filings since Nov 12, 2024)
- Bradley A. Keywell Filed SCHEDULE 13G/A on Tempus AI, latest May 15, 2025 (2 filings since Aug 8, 2024)
- Tempus AI Chicago, Illinois, United States
- Personalis (United States) Stake · Menlo Park, California, United States
- Arterys Inc. (Canada) Subsidiary · Canada
- Arterys SAS (France) Subsidiary · France
- OneOme PGx Europe Limited Subsidiary · Ireland
- Paige.AI GmbH Subsidiary · Germany
- Tempus AI Spain, SL Subsidiary · Spain
- Tempus Labs Singapore PTE. LTD Subsidiary · Singapore
Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G; stakes of 5% or more it reported on Schedules 13D and 13G (1 companies). Each entity in the chart links to its source.
What it owns
What Tempus AI reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Land and buildings | $9.8M6 Dec 31, 2025 | $06 Dec 31, 2024 | |
| Buildings and improvements | $1.2M6 Dec 31, 2025 | $06 Dec 31, 2024 | |
| Machinery and equipment | $143.7M6 Dec 31, 2025 | $110.0M6 Dec 31, 2024 | +30.6% |
| Furniture and fixtures | $7.0M6 Dec 31, 2025 | $6.6M6 Dec 31, 2024 | +5.2% |
| Leasehold improvements | $64.8M6 Dec 31, 2025 | $46.8M6 Dec 31, 2024 | +38.4% |
| Property and equipment, before depreciation | $226.5M6 Dec 31, 2025 | $163.5M6 Dec 31, 2024 | +38.6% |
| Accumulated depreciation | $137.3M6 Dec 31, 2025 | $105.4M6 Dec 31, 2024 | +30.3% |
| Property and equipment, net | $89.2M6 Dec 31, 2025 | $58.1M6 Dec 31, 2024 | +53.6% |
| Operating-lease assets (leased space) | $64.5M6 Dec 31, 2025 | $14.8M6 Dec 31, 2024 | +336.9% |
Investments
| Item | Latest | A year before | Change |
|---|---|---|---|
| Cash and cash equivalents | $604.8M6 Dec 31, 2025 | $341.0M6 Dec 31, 2024 | +77.4% |
| Equity securities at fair value | $150.2M6 Dec 31, 2025 | $107.3M6 Dec 31, 2024 | +40.0% |
Intangibles and goodwill
| Item | Latest | A year before | Change |
|---|---|---|---|
| Goodwill | $470.2M6 Dec 31, 2025 | $73.3M6 Dec 31, 2024 | +541.1% |
| Intangible assets, net (excluding goodwill) | $355.3M6 Dec 31, 2025 | $11.7M6 Dec 31, 2024 | +2932.2% |
| Accumulated amortization | $107.1M6 Dec 31, 2025 | $36.9M6 Dec 31, 2024 | +190.6% |
| Finite-lived intangibles, net | $355.2M6 Dec 31, 2025 | $11.7M10 Dec 31, 2024 | +2937.0% |
Inventory
| Item | Latest | A year before | Change |
|---|---|---|---|
| Inventory, total | $51.7M6 Dec 31, 2025 | $38.4M6 Dec 31, 2024 | +34.7% |
| Work in process | $1.7M6 Dec 31, 2025 | $1.5M6 Dec 31, 2024 | +13.3% |
Properties, in its own words
Our headquarters is located in Chicago, Illinois, where we lease approximately 217,000 square feet of laboratory and office space pursuant to a lease that expires in May 2029. We also lease an aggregate of approximately 22,000 square feet of laboratory and office space in Atlanta, Georgia pursuant to a lease that will expire in December 2029. Our CLIA-certified laboratories are located in these facilities. We also lease genomics labs in Raleigh, North Carolina, and Minneapolis, Minnesota and own our lab in Aliso Viejo, California. We also lease offices in New York, New York, Redwood City, California and Aliso Viejo, California. We also own 92,695 square feet of land in Aliso Viejo, California. While we believe our existing facilities are adequate to meet our current requirements, we expect to expand our facilities as our operations grow over time. We believe we will be able to obtain such additional space on acceptable and commercially reasonable terms.
Item 2 of the 10-K filed Feb 24, 2026.15
Leadership
Who has led Tempus AI, and when. Pick a name to see everywhere that person has worked.
Chief executive
Chief operating officer
2025
- Chief executive officerRyan Fukushima Feb 20, 2026 to Feb 25, 202616
- Chief executive officerThomas Edward Schoenherr Feb 25, 2026 to now17
- Chief operating officerRyan Fukushima Jun 13, 2024 to now18
Board members and other officers (11)
- EVP & Chief Admin & Legal OffErik Phelps Jun 13, 2024 to now19
- Chief Accounting OfficerRyan M. Bartolucci Jun 17, 2024 to now20
- Board memberDavid R. Epstein Jun 13, 2024 to now21
- Board memberEric D. Belcher Jun 13, 2024 to now22
- Board memberJennifer Doudna Jun 13, 2024 to now23
- Board memberNadja West Jun 13, 2024 to now24
- Board memberPeter J. Barris Jun 13, 2024 to now25
- Board memberScott Gottlieb Jun 13, 2024 to now26
- Board memberTheodore Leonsis Jun 13, 2024 to now27
- Board memberWayne A.I. Frederick Jun 13, 2024 to now28
- General counselAndrew Polovin Jun 13, 2024 to now29
Named in SEC Form D filings
People the company listed in its private-offering notices.
Products and brands
Tempus does genome sequencing and precision medicine, including diagnostics, primarily for cancer patients, as well as for cardiology patients, radiology, and pharmacogenomic testing for patients with depression. It is headquartered in Chicago.
Tempus investors include SoftBank Group, Baillie Gifford, New Enterprise Associates, Novo Holdings, Franklin Templeton Investments, T. Rowe Price, Revolution LLC, Google LLC, and others.
In June 2024, Tempus and SoftBank formed an AI healthcare joint venture in Japan called SB Tempus with a plan to develop personalized treatment recommendations by analyzing medical data with AI. In November that year, Tempus agreed to acquire California-based genetic testing company Ambry Genetics for $600 million in a cash-and-stock deal.
In July 2026, Tempus agreed to acquire cancer-testing company Personalis in a deal valued at approximately US$1.5 billion. The acquisition would add Personalis's NeXT Personal cancer test to Tempus's oncology portfolio and is expected to close in late 2026 or early 2027.
Read the full text
The company's advisory board includes Jennifer Doudna and Scott Gottlieb. At the end of 2025, Tempus employs around 3,800 people.
From Wikipedia’s article on Tempus AI, shared under CC BY-SA 4.0.8
Subsidiaries and ownership
Subsidiaries (Exhibit 21)
- Arterys Inc. (Canada) Canada9
- Arterys SAS (France) France9
- OneOme PGx Europe Limited Ireland9
- Paige.AI GmbH Germany9
- Paige.AI LTD United Kingdom9
- Tempus AI Spain, SL Spain9
- Tempus Labs Singapore PTE. LTD Singapore9
The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.
Former names
- Tempus Labs, Inc.Sep 25, 2017 to Dec 5, 20237
Timeline
- Jul 30, 20268-K Results of operations; Regulation FD disclosure31
- Jul 20, 20268-K Regulation FD disclosure32
- Jul 20, 20268-K Entered a material agreement33
- May 22, 20268-K Shareholder vote34
- May 13, 20268-K Entered a material agreement; Ended a material agreement; New debt or obligation35
- May 5, 20268-K Results of operations; Regulation FD disclosure36
- Feb 25, 2026New chief executive Thomas Edward Schoenherr becomes CEO17
- Feb 24, 20268-K Results of operations; Regulation FD disclosure37
- Feb 20, 2026New chief executive Ryan Fukushima becomes CEO16
- Jan 12, 20268-K Results of operations; Regulation FD disclosure38
- Nov 4, 20258-K Results of operations; Regulation FD disclosure39
- Aug 27, 20258-K Other events40
- Aug 8, 20258-K Results of operations; Regulation FD disclosure41
- Jul 3, 20258-K Entered a material agreement; New debt or obligation; Unregistered sale of shares42
- Jun 14, 2024Went public Listed on NASDAQ1
- Aug 26, 2015Founded Tempus AI is founded4
Calendar
Coming up
- Nov 2, 2026 · Before the openReports results for the quarter ending Sep/2026 A year earlier it reported ($0.31) a share, on Nov 4, 2025.43
When it reported results
- Jul 30, 2026Reported quarterly or annual results31
- May 5, 2026Reported quarterly or annual results36
- Feb 24, 2026Reported quarterly or annual results37
- Jan 12, 2026Reported quarterly or annual results38
- Nov 4, 2025Reported quarterly or annual results39
- Aug 8, 2025Reported quarterly or annual results41
- May 6, 2025Reported quarterly or annual results44
- Feb 24, 2025Reported quarterly or annual results45
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar
Filings
486 filings to the SEC since October 2021: 2 annual reports, 7 quarterly reports, 24 major events, 232 insider forms, 16 large holders, 1 private raises, 204 other. The latest 20:
- Oct 2, 2026S-4/A EDGAR
- Sep 29, 20264 EDGAR
- Sep 25, 2026144 EDGAR
- Sep 24, 20264 EDGAR
- Sep 22, 2026144 EDGAR
- Sep 18, 20264 EDGAR
- Sep 18, 20264 EDGAR
- Sep 18, 20264 EDGAR
- Sep 18, 20264 EDGAR
- Sep 17, 2026144 EDGAR
- Sep 17, 2026144 EDGAR
- Sep 17, 2026144 EDGAR
- Sep 16, 2026144 EDGAR
- Sep 15, 2026425 EDGAR
- Sep 3, 20264 EDGAR
- Sep 3, 20264 EDGAR
- Sep 3, 20264 EDGAR
- Sep 1, 2026144 EDGAR
- Sep 1, 2026144 EDGAR
- Sep 1, 20264 EDGAR
The 486 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
189 open-market trades by officers, directors and large owners since October 2021: 0 buys and 189 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 25, 2026 | Schoenherr Thomas EdwardCEO, Diagnostics | Sale | 10,281 | $85.00 | $873.9K | Form 4 |
| Sep 22, 2026 | LEFKOFSKY ERIC PCEO and Chairman | Sale | 250,000 | $77.47 | $19.4M | Form 4 |
| Sep 17, 2026 | Polovin AndrewEVP, Chief Legal Officer | Sale | 2,951 | $75.00 | $221.3K | Form 4 |
| Sep 17, 2026 | Bartolucci Ryan MChief Accounting Officer | Sale | 7,062 | $75.00 | $529.6K | Form 4 |
| Sep 17, 2026 | LEFKOFSKY ERIC PCEO and Chairman | Sale | 200,000 | $80.57 | $16.1M | Form 4 |
| Sep 16, 2026 | Fukushima RyanCEO, Data | Sale | 700 | $70.00 | $49.0K | Form 4 |
| Sep 1, 2026 | Fukushima RyanCEO, Data | Sale | 30,846 | $62.71 | $1.9M | Form 4 |
| Sep 1, 2026 | Doudna Jennifer ADirector | Sale | 676 | $65.55 | $44.3K | Form 4 |
| Sep 1, 2026 | Epstein David RDirector | Sale | 250 | $65.55 | $16.4K | Form 4 |
| Aug 28, 2026 | West NadjaDirector | Sale | 3,000 | $69.00 | $207.0K | Form 4 |
| Aug 25, 2026 | LEFKOFSKY ERIC PCEO and Chairman | Sale | 11,848 | $69.87 | $827.9K | Form 4 |
| Aug 25, 2026 | LEFKOFSKY ERIC PCEO and Chairman | Sale | 238,152 | $68.39 | $16.3M | Form 4 |
| Aug 21, 2026 | Schoenherr Thomas EdwardCEO, Diagnostics | Sale | 2,694 | $70.00 | $188.6K | Form 4 |
| Aug 21, 2026 | Fukushima RyanCEO, Data | Sale | 14,286 | $70.00 | $1.0M | Form 4 |
| Aug 19, 2026 | Schoenherr Thomas EdwardCEO, Diagnostics | Sale | 8,082 | $58.40 | $472.0K | Form 4 |
| Aug 19, 2026 | Rogers James WilliamChief Financial Officer | Sale | 26,313 | $60.00 | $1.6M | Form 4 |
| Aug 19, 2026 | Polovin AndrewEVP, Chief Legal Officer | Sale | 7,927 | $56.00 | $443.9K | Form 4 |
| Aug 18, 2026 | Schoenherr Thomas EdwardCEO, Diagnostics | Sale | 9,232 | $49.61 | $458.0K | Form 4 |
| Aug 18, 2026 | Rogers James WilliamChief Financial Officer | Sale | 22,529 | $49.61 | $1.1M | Form 4 |
| Aug 18, 2026 | Fukushima RyanCEO, Data | Sale | 41,095 | $49.61 | $2.0M | Form 4 |
All 189 trades can be filtered by person here when JavaScript is on.
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- BAILLIE GIFFORD & COSCHEDULE 13G/A, 4 filings Nov 5, 2024 to May 7, 202646
- VANGUARD GROUP INCSCHEDULE 13G/A, 2 filings Oct 31, 2025 to Mar 27, 202647
- ARK Investment Management LLCSCHEDULE 13G, 1 filing Mar 6, 202648
- Eric P. LefkofskySCHEDULE 13G/A, 3 filings Nov 12, 2024 to Feb 10, 202649
- Red Sky Ventures LLCSCHEDULE 13G/A, 4 filings Nov 12, 2024 to Nov 13, 202550
- Bradley A. KeywellSCHEDULE 13G/A, 2 filings Aug 8, 2024 to May 15, 202551
Stakes it holds
Tempus AI has told the SEC it owns more than 5% of 1 company, latest first (Schedules 13D and 13G).
- Personalis (United States)SCHEDULE 13D/A Dec 5, 2023 to Jul 21, 202652
Executive pay
What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.
| Year | Executive | Age | Salary | Total pay |
|---|---|---|---|---|
| 2025 | Eric LefkofskyChief Executive Officer, Founder and Chairman | 56 | $783.3K | $41.5M53 |
| 2025 | Ryan FukushimaChief Executive Officer, Data | 40 | $422.7K | $11.6M53 |
| 2025 | Andrew PolovinExecutive Vice President, Chief Legal Officer and Secretary | 52 | $610.0K | $6.6M53 |
| 2025 | James RogersChief Financial Officer | 40 | $500.0K | $6.4M53 |
| 2025 | Erik PhelpsExecutive Vice President, Chief Administrative and Legal Officer and Assistant Secretary | $610.0K | $4.6M53 | |
| 2024 | Eric LefkofskyChief Executive Officer, Founder and Chairman | 56 | $800.0K | $28.6M53 |
| 2024 | Ryan FukushimaChief Executive Officer, Data | 40 | $375.0K | $4.6M53 |
| 2024 | Andrew PolovinExecutive Vice President, Chief Legal Officer and Secretary | 52 | $591.7K | $2.7M53 |
| 2024 | James RogersChief Financial Officer | 40 | $500.0K | $2.7M53 |
| 2023 | James RogersChief Financial Officer | 40 | $491.7K | $3.3M53 |
| 2023 | Eric LefkofskyChief Executive Officer, Founder and Chairman | 56 | $2.1K53 |
Money raised
Private offerings the company reported to the SEC on Form D.
- Oct 3, 2022Raised $10 million in a private offering of equity Form D: 4 investors so far Form D
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| ARK Investment Management LLC | 10,022,634 | $580.6M | 3.8% | +414,889 |
| BlackRock, Inc. | 8,291,053 | $480.3M | 0.0% | −677,277 |
| Baillie Gifford & Co | 8,190,133 | $474.5M | 0.4% | −459,223 |
| Softbank Group Corp. | 5,405,406 | $313.1M | 1.7% | No change |
| Jpmorgan Chase & Co | 4,989,062 | $291.2M | 0.0% | +55,869 |
| Vanguard Capital Management LLC | 4,988,038 | $289.0M | 0.0% | +69,916 |
| Vanguard Portfolio Management LLC | 4,914,410 | $284.7M | 0.0% | +235,353 |
| Sumitomo Mitsui Trust Group, Inc. | 4,089,029 | $236.9M | 0.1% | −237,284 |
| Amova Asset Management Americas, Inc. | 4,089,029 | $236.6M | 3.1% | −237,284 |
| Goldman Sachs Group Inc | 3,761,666 | $217.9M | 0.0% | +2,483,910 |
| Morgan Stanley | 3,652,136 | $211.6M | 0.0% | +1,568,701 |
| Franklin Resources Inc | 3,352,768 | $194.2M | 0.0% | +771,124 |
| UBS Group AG | 2,546,634 | $147.5M | 0.0% | −687,753 |
| Citadel Advisors LLC | 2,512,401 | $145.5M | 0.1% | +1,911,096 |
| GC Wealth Management RIA, LLC | 2,411,368 | $139.7M | 8.1% | −4,199,843 |
| Geode Capital Management, LLC | 2,092,519 | $121.2M | 0.0% | +152,312 |
| Bank Of America Corp /de/ | 1,917,772 | $111.1M | 0.0% | +1,502,992 |
| State Street Corp | 1,887,599 | $109.3M | 0.0% | +197,838 |
| Alphabet Inc. | 1,551,102 | $89.9M | 0.1% | No change |
| Jane Street Group, LLC | 1,428,847 | $82.8M | 0.1% | +759,993 |
| Lingotto Investment Management LLP | 1,415,766 | $82.0M | 1.8% | No change |
| Clear Street Group Inc. | 1,345,069 | $77.9M | 0.2% | +389,487 |
| Legal & General Group Plc | 1,145,900 | $66.4M | 0.0% | +374,526 |
| Norges Bank | 975,302 | $56.5M | 0.0% | New |
| Bamco Inc /ny/ | 904,259 | $52.4M | 0.1% | +4,981 |
13F reports cover disclosed long positions in U.S. stocks only.
Members of Congress who traded it
1 trades disclosed by members of Congress. “Vs S&P since” is the stock’s change since the trade minus the S&P 500’s.
| Date | Member | Trade | Amount | Vs S&P since | Filing |
|---|---|---|---|---|---|
| Jan 14, 2025 | Nancy PelosiDemocratic, House | Buy | $50,001 - $100,000 | +95.6% | Report |
Members report amounts as ranges, not exact figures. Returns are price-only (no dividends).
SEC filer profile
How Tempus AI is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARTempus AI, Inc.2
- CIK0001717115
- Employer ID (EIN)47-490330815
- Filer statusLarge accelerated filer not an emerging growth company; not a smaller reporting company; not a shell company15
- Incorporated inNevada15
- Fiscal year endsDecember 312
- Industry code (SIC)7370 Services-Computer Programming, Data Processing, Etc.2
- SEC reviewing officeOffice of Technology, Division of Corporation Finance2
- Business address600 West Chicago Avenue, Suite 510, Chicago, IL 606542
- Phone800-976-54482
- Shares outstanding173,729,901 Common Class A shares; 5,043,789 Common Class B shares as of Feb 20, 202615
- Public float$11.0B as of Jun 30, 202515
- AuditorPricewaterhouseCoopers LLP, Chicago, Illinois PCAOB ID 238; it also attests to the company’s internal control over financial reporting15
- On EDGAR sinceSep 25, 20172
- Filings500 in all: 4 (215), 144 (135), 8-K (24), 3 (18), DRSLTR (11), UPLOAD (11), DRS/A (10), SCHEDULE 13G/A (9)2
All 39 form types
10-Q (7), 425 (6), D (4), SC 13G (4), SCHEDULE 13G (4), 424B3 (3), CORRESP (3), S-8 (3), 10-K (2), 4/A (2), ARS (2), DEF 14A (2), DEFA14A (2), EFFECT (2), S-1 (2), S-1/A (2), S-8 POS (2), SCHEDULE 13D/A (2), 424B4 (1), 424B7 (1), 8-A12B (1), CERT (1), DEF 14C (1), DRS (1), PRE 14A (1), PRE 14C (1), S-3ASR (1), S-4 (1), S-4/A (1), SC 13D (1), SC 13D/A (1)
- Latest filingsAnnual report (10-K) Feb 24, 2026
Quarterly report (10-Q) Jul 30, 2026
Proxy statement (DEF 14A) Apr 7, 2026
Latest 8-K (8-K) Jul 30, 2026
Securities registered for trading
| Class | Symbol | Exchange |
|---|---|---|
| Class A common stock, $0.0001 par value per share | TEM | The Nasdaq Stock Market LLC |
From the cover page of the 10-K filed Feb 24, 2026 (Section 12(b) of the Exchange Act).15
Risk factors and legal proceedings
The risks Tempus AI names in Item 1A of its 10-K filed Feb 24, 2026: 77 risks under these headings, as written.15
- We have incurred significant losses since inception, we may continue to incur losses in the future, and we may not be able to generate sufficient revenue to achieve and maintain profitability.
- Our current or future products may not achieve or maintain sufficient commercial market acceptance.
- Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations or any guidance we may provide.
- The success of our business depends on our continued access to, and ability to monetize, de-identified patient data.
- Our limited operating history and rapid growth make it difficult to evaluate our future prospects and the risks and challenges we may encounter.
- We may need to raise additional capital to fund our existing operations, develop our Platform, commercialize new products or expand our operations.
- Our Applications product line is nascent.
- Our diagnostic products, or our competitors’ diagnostic products, could have defects or errors or otherwise fail to meet the expectations of patients, physicians and third-party payers; in such cases our operating results, reputation and business could suffer.
- If third-party payers, including commercial payers and government healthcare programs, do not provide coverage of, or adequate reimbursement for, or reverse or change their policies related to our tests, our business, financial condition and results of operations will be negatively affected.
- If we are unable to obtain or maintain adequate reimbursement for our Diagnostics product line outside of the United States, our ability to expand internationally will be compromised.
- Labor relations matters could have a material adverse effect on our business, reputation, prospects, results of operations and financial condition.
- We use AI in our products and services which may result in operational challenges, legal liability, reputational concerns and competitive risks.
The other 65 risks
- If we cannot compete successfully with our competitors, we may be unable to increase or sustain our revenue or to achieve and then sustain profitability.
- The industries in which we operate are subject to rapid change, which could make our Platform, our current products and any future products we may develop obsolete.
- Our existing and any future debt may affect our flexibility in operating and developing our business and our ability to satisfy our obligations.
- We rely on a limited number of suppliers or, in some cases, sole suppliers, for some of our laboratory instruments and materials and may not be able to find replacements or promptly transition to alternative suppliers.
- International expansion of our business exposes us to business, regulatory, political, operational, financial, and economic risks associated with doing business outside of the United States.
- We conduct business in a heavily regulated industry, and changes in regulations or violations of regulations may, directly or indirectly, reduce our revenue, adversely affect our business, financial condition and results of operations.
- Certain of our tests are currently marketed as LDTs, and future changes in FDA enforcement discretion for LDTs could subject our operations to much more significant regulatory requirements.
- If we are unable to obtain, maintain and enforce sufficient intellectual property protection for our Platform and products, or if the scope of the intellectual property protection obtained is not sufficiently broad, our competitors or other third parties could develop and commercialize products similar or identical to ours, and our ability to successfully commercialize our products may be impaired.
- We are and may in the future become involved in litigation and other legal proceedings alleging that we are infringing, misappropriating or otherwise violating third-party intellectual property rights, or asserting our intellectual property rights, which could be time-intensive and costly and may adversely affect our business, financial condition and results of operations.
- We have and may in the future acquire businesses, form joint ventures or make investments in companies or technologies that could negatively affect our operating results, distract management’s attention from other business concerns, dilute our stockholders’ ownership, and significantly increase our debt, costs, expenses, liabilities and risks.
- We are highly dependent on the services of Eric Lefkofsky and other members of our senior management team and the loss of any member of our senior management team or our inability to attract and retain highly skilled scientists, clinicians, sales representatives and business development managers could adversely affect our business, financial condition and results of operations.
- If our information technology systems or those third parties with whom we work or our data, are or were compromised, we could experience adverse consequences resulting from such compromise, including but not limited to regulatory investigations or actions; litigation; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; loss of customers or sales; and other adverse consequences.
- The dual class structure of our common stock has the effect of concentrating voting control with our Chief Executive Officer, Founder and Chairman, which will limit your ability to influence the outcome of important decisions.
- Our stock price may be volatile, and the value of our Class A common stock may decline.
- We depend on information technology systems, including on-premises, co-located and third-party data centers and platforms, and any interruptions of service or failures may impair and harm our business, financial condition and results of operations.
- Risks Related to Our Business and Strategy
- The continued adoption of our products and services is dependent on a number of factors, many of which are interrelated.
- New product development and commercialization involve a lengthy and complex process and we may be unable to develop or commercialize new products on a timely basis, or at all.
- We may not be successful in updating or otherwise enhancing our Platform and products.
- If we are not successful in leveraging our Platform to identify, develop and commercialize additional genomic and algorithmic tests, our ability to expand our business and achieve our strategic objectives would be impaired.
- If our existing and new products fail to achieve and sustain sufficient scientific acceptance, we will not generate expected revenue and our prospects may be harmed.
- Our diagnostic products, or our competitors’ diagnostic products, could have defects or errors or otherwise fail to meet the expectations of patients, healthcare providers, and third-party payers; in such cases our operating results, reputation and business could suffer.
- If we are unable to support demand for our current and future Diagnostics product line, including ensuring that we have adequate capacity to meet increased demand, or we are unable to successfully manage our anticipated growth, our business could suffer.
- Ethical, legal and social concerns related to the use of genetic information could reduce demand for our tests.
- Our use of AI tools may pose particular risks to our proprietary software and systems and subject us to legal liability.
- We may experience challenges with the acquisition, development, enhancement or deployment of technology necessary for our businesses.
- The sizes of the markets for our current and future products have not been established with precision, and may be smaller than we estimate.
- Our research and development strategy emphasizes rapid innovation and advancement of successful hires who may not have prior industry expertise, and we frequently prioritize patient care and customer satisfaction over short-term financial results. If we cannot maintain or properly manage our culture as we grow, our business may be harmed.
- We may not be able to successfully market, sell or distribute our products, and if we are unable to expand our sales organization to adequately address our customers’ needs, our business, financial condition and results of operations may be adversely affected.
- If we are not successful in executing our strategy to increase sales of our Data and applications products to large pharmaceutical and biotechnology customers, our results of operations may suffer.
- If our existing customers do not renew their licenses, do not buy additional products from us, or renew at lower prices, our business and operating results will suffer.
- A significant portion of our Data and applications product line revenue are generated by sales to life sciences industry customers, and factors that adversely affect this industry could also adversely affect our Data and applications business sales.
- We have invested and expect to continue to invest in research and development efforts that further enhance our data analytics. Such investments may affect our operating results, and, if the return on these investments is lower or develops more slowly than we expect, our revenue and operating results may suffer.
- If we are unable to collect receivables from our customers, our operating results may be adversely affected.
- Certain disruptions in supply of, and changes in the competitive environment for, raw materials and components integral to the manufacturing of our products may adversely affect our ability to achieve and maintain profitability.
- If our existing laboratory and storage facilities become damaged or inoperable or we are required to vacate our existing facilities, our ability to perform our tests and pursue our research and development efforts may be jeopardized.
- We rely on commercial courier delivery services to transport samples to our laboratory facility in a timely and cost-efficient manner and if these delivery services are disrupted, our business will be harmed.
- If we cannot provide quality technical support and services for our Data and applications products, we could lose customers and our business and prospects will suffer.
- Seasonality may cause fluctuations in our revenue and results of operations.
- Risks Related to Our Highly Regulated Industry
- There is no guarantee that the FDA will grant 510(k) clearance or a premarket approval or that comparable foreign regulatory authorities will grant the necessary clearance, approval or certification of our products and failure to obtain necessary clearances, approvals or certification for our products would adversely affect our ability to grow our business.
- Modifications to our FDA-cleared, approved or CE marked products may require new 510(k) clearances or premarket approvals or certification, or may require us to cease marketing or recall the modified products until clearances are obtained.
- Our products may in the future be subject to product recalls. A recall of our products, either voluntarily or at the direction of the FDA or another governmental authority or regulatory authority, or the discovery of serious safety issues with our products, could have a significant adverse impact on us.
- Our “research use only” and any potential “investigational use only” products could become subject to more onerous regulation by the FDA or other regulatory authorities in the future, which could increase our costs and delay our commercialization efforts, thereby materially and adversely affecting our business, financial condition and results of operations.
- Even if we receive regulatory approval or certification of our products, we will continue to be subject to extensive regulatory oversight.
- We may never obtain approval or certification in foreign jurisdictions for any of our products and, even if we do, we may never be able to commercialize them in any other jurisdiction, which would limit our ability to realize their full market potential.
- Failure to comply with federal, state and foreign laboratory licensing requirements and the applicable requirements of the FDA or any other regulatory authority, could cause us to lose the ability to perform our tests, experience disruptions to our business, or become subject to administrative or judicial sanctions.
- We are subject to numerous federal, state and foreign healthcare statutes and regulations; complying with such laws pertaining to our business is an expensive and time-consuming process, and any failure to comply could result in substantial penalties and a material adverse effect to our business, financial condition and results of operations.
- If the validity of an informed consent from patients regarding our tests was challenged, we could be forced to stop offering our products or using our resources, and our business, financial condition and results of operations could be negatively affected.
- We may be subject to fines, penalties, licensure requirements, or legal liability, if it is determined that through our test reports we are practicing medicine without a license.
- Our billing and claim processing are complex and time-consuming, and any delay in submitting claims or failure to comply with applicable billing requirements could hinder collection and have an adverse effect on our revenue.
- Changes in healthcare laws, regulations and policies could increase our costs, decrease our sales and revenue and negatively impact reimbursement for our tests.
- We face risks related to handling of hazardous materials and other regulations governing environmental safety.
- We could be adversely affected by violations of the FCPA and other anti-bribery laws.
- Risks Related to Our Intellectual Property
- Changes in patent law in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our Platform and products.
- Issued patents covering our Platform or products could be found invalid or unenforceable if challenged.
- We rely on licenses from third parties to provide certain products, and if we lose these licenses or if our rights under these licenses are limited, then our business will be adversely impacted.
- If we cannot license and maintain rights to use third-party intellectual property on reasonable terms, we may not be able to successfully commercialize our products. Our licensed or acquired technology may lose value or utility over time.
- We may not be able to protect or enforce our intellectual property rights adequately throughout the world.
- If we are unable to protect the confidentiality of our trade secrets, the value of our Platform and other technology could be materially adversely affected and our business could be harmed.
- We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties or that our employees have wrongfully used or disclosed trade secrets of their former employers.
- We may not be able to protect and enforce our trademarks and we could infringe or otherwise violate others’ trademarks and if our trademarks are not adequately protected, then we may not be able to build name recognition in our markets of interest.
- We may be subject to claims challenging the inventorship or ownership of our owned or licensed intellectual property or claims asserting ownership of what we regard as our own intellectual property.
- Obtaining and maintaining our patent and trademark protection depends on compliance with various required procedures, document submissions, fee payments and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.
- Patent terms may be inadequate to protect our competitive position for an adequate amount of time.
- Intellectual property rights do not necessarily address all potential threats.
- Our products contain third-party open source software components and failure to comply with the terms of the underlying open source software licenses could restrict our ability to sell our products or may require us to publicly disclose our proprietary software.
Legal proceedings
From time to time, we may be involved in various legal proceedings, including commercial claims from customers and vendors, potential lawsuits seeking damages and/or injunctive relief, employment disputes, subpoenas, government investigations, regulatory or administrative proceedings, and other types of matters arising from the normal course of business activities. We may also initiate such proceedings against various third parties. Defending against and pursuing such proceedings is costly and can impose a significant burden on management and employees. The results of any current or future litigation cannot be predicted with certainty, and regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources, and other factors. Except as described below, we believe there are currently no pending legal proceedings to which we or our property are subject that could have a material adverse effect on our financial position, results of operations or cash flows.
In other instances, although no formal legal proceeding has been instituted, from time to time, we receive requests from governmental agencies, or third parties working on their behalf, for documents and information related to our products and services. For example, on May 19, 2022, we received a subpoena from the Office of the Ohio Attorney General. The subpoena required production of certain billing and patient records associated with nine Ohio Medicaid patients who received our clinical diagnostic tests between 2019 and 2022. We provided responsive documents in June 2022 and have not received additional inquiry from the Ohio Attorney General’s office since that time.
The opening of Item 3, Legal Proceedings.15
Links
- Websitewww.tempus.com1
- WikipediaTempus AI
- WikidataQ127040202
- SEC EDGARCIK 1717115
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1WikidataTempus AI on Wikidata
- 2SEC EDGARTempus AI filings on SEC EDGAR
- 3WikipediaTempus AI on Wikipedia
- 4
- 5Wikimedia CommonsTempus AI logo by Tempus AI, Public domain
- 6SEC EDGARTempus AI 10-K for fiscal 2025
- 7SEC EDGARTempus AI filings on SEC EDGAR
- 8
- 9
- 10SEC EDGARTempus AI 10-K for fiscal 2022
- 11SEC EDGARTempus AI 10-Q for fiscal 2025
- 12SEC EDGARTempus AI 10-Q for fiscal 2025
- 13SEC EDGARTempus AI 10-Q for fiscal 2026
- 14SEC EDGARTempus AI 10-Q for fiscal 2025
- 15
- 16
- 17
- 18
- 19
- 20
- 21SEC EDGARDavid R. Epstein, Board member
- 22SEC EDGAREric D. Belcher, Board member
- 23SEC EDGARJennifer Doudna, Board member
- 24SEC EDGARNadja West, Board member
- 25SEC EDGARPeter J. Barris, Board member
- 26SEC EDGARScott Gottlieb, Board member
- 27SEC EDGARTheodore Leonsis, Board member
- 28SEC EDGARWayne A.I. Frederick, Board member
- 29SEC EDGARAndrew Polovin, General counsel
- 30
- 31
- 32SEC EDGARRegulation FD disclosure
- 33SEC EDGAREntered a material agreement
- 34SEC EDGARShareholder vote
- 35
- 36
- 37
- 38
- 39
- 40SEC EDGAROther events
- 41
- 42
- 43NasdaqNasdaq calendar
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53